The antidote market is witnessing substantial growth, largely propelled by the growing incidence of poisoning, drug overdoses, and snake or animal bites. This rising demand is supported by greater ...

Shares in Wise PLC spiked almost 10% on Thursday after the global payments solutions provider announced it would be ...

U.S. steel stocks, more. Wall Street sees more weakness ahead for U.S. dollar. Indivior to delist from London Stock Exchange, ...

Indivior said the decision to delist from London reflects its increasingly US-focused operations, with over 80% of revenue now generated stateside and about 75% of trading volume occurring on Nasdaq.

Indivior (INDV) on Monday said that it will cancel its secondary listing on the London Stock Exchange, effective July 25, ...

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align ...

The British pharmaceuticals company said the US exchange offers the ‘most attractive and valuable opportunity set’ ...

Drug maker Indivior to abandon London stock market for the US - Indivior’s exit comes after the company moved its primary ...

Indivior said it would cancel its listing on the London Stock Exchange and keep its primary listing on New York City's Nasdaq stock exchange.

Australian biotech TekCyte Limited appointed a new co-CEO leadership team consisting of Tony Simula, TekCyte’s founding CEO, as well as Tara James, a commercial strategist and founder of Small and ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...

Over the last year, a good number of insiders have significantly increased their holdings in Indivior PLC (LON:INDV). This is encouraging because it indicates that insiders are more optimistic ...